FUNCTIONAL AREAS – Page 12

Training evidence weak during regulatory inspection readiness – GDP documentation do’s and don’ts

Addressing Weak Training Evidence During Regulatory Inspections in Pharma In the pharmaceutical industry, the robustness of training documentation is paramount for compliance during regulatory inspections. Weak training evidence can lead…

Supplier deviation not assessed during QA review – GDP documentation do’s and don’ts

Assessing Supplier Deviations During QA Reviews: An Investigation Guide In pharmaceutical manufacturing, the failure to adequately assess supplier deviations during Quality Assurance (QA) reviews can pose significant risks to product…

Training evidence weak during batch release decision – FDA/MHRA inspector questions to prepare for

Identifying symptoms of weak training evidence is crucial to trigger prompt investigations. Common signals include:Click to read the full article.

Deviation closed without effectiveness check during internal audit follow-up – regulatory expectation gap and how to fix it

Identifying the signs that a deviation was closed without proper validation is crucial for early intervention. In pharmaceutical operations, several indicators may point to this issue:Click to read the full…

CAPA overdue beyond target date during batch release decision – GDP documentation do’s and don’ts

Signals indicating that a CAPA is overdue during batch release typically manifest as deviations or complaints. Examples include:Click to read the full article.

Inconsistent SOP interpretation during management review – regulatory expectation gap and how to fix it

Identifying symptoms of inconsistent SOP interpretation at an early stage is crucial for effective management review processes. Symptoms might manifest in various forms, including but not limited to:Click to read…

Supplier deviation not assessed during complaint triage – CAPA effectiveness verification framework

Identifying symptoms of a potential supplier deviation during complaint triage is crucial. Signs can manifest in various ways:Click to read the full article.

Inconsistent SOP interpretation during management review – risk-based justification template for decisions

Identifying symptoms of inconsistent SOP interpretations is critical for a proactive response. Common indicators may include:Click to read the full article.

Batch disposition delayed during QA review – risk-based justification template for decisions

Identifying the initial symptoms indicating a delay in batch disposition is crucial for initiating an effective investigation. Common signals that suggest a problem may exist include:Click to read the full…

Batch disposition delayed during change control governance – how to prevent repeat observations

Identifying symptoms of batch disposition delay at the outset is crucial for effective investigation and resolution. Some common signals include:Click to read the full article.

Inconsistent SOP interpretation during complaint triage – GDP documentation do’s and don’ts

Identifying the initial symptoms or signals indicative of inconsistent SOP interpretation is the first step in mitigating potential risks associated with product quality. Common scenarios might include:Click to read the…

Quality event trending ignored during internal audit follow-up – how to prevent repeat observations

Recognizing symptoms that suggest trends in quality events are not adequately addressed is crucial for prevention. These signals can manifest in various forms:Click to read the full article.